ORCHARD PARK, N.Y.,
Dec. 31, 2020 /PRNewswire/
-- Buffalo Bills, 2020 AFC East Division Champions, and
BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), today announced they will be performing fan testing
for the AFC Divisional Wild Card playoff game at Bills Stadium in
Orchard Park.
Through New York State, the
Bills have been granted permission to host fans at their home Wild
Card game that will be played on Jan.
9 or 10. All fans will be required to obtain a negative
COVID-19 PCR laboratory-based test result within 72 hours of the
game through the NFL's testing partner, BioReference, in order to
attend the game. Fans that purchase a ticket will be given a
BioReference URL to select a testing time at Bills Stadium, two or
three days prior to game day.
"BioReference has been helping our players, coaches and staff
stay safe all season," said Kim
Pegula, Bills Owner and President. "We have no doubt
they will help create a safe environment for our long awaited home
playoff game. We are pleased to expand our partnership to bring
fans back into the stadium."
"The Bills, New York State and
BioReference are committed to providing a safe environment so that
fans can enjoy the playoff game," said Jon R. Cohen, M.D., Executive Chairman of
BioReference Laboratories. "BioReference has led the way in
providing customized large scale COVID-19 screening programs to
organizations and municipalities across the country. Fan testing is
the next natural step in helping Americans attend and enjoy live
sporting and entertainment events."
"Bills fans have waited decades in order to attend a home
playoff game and we have worked to build an innovative pilot
program to make that happen safely," Governor Cuomo
said. "All season long, the Bills' stellar play has
captured a certain energy and charisma that is undoubtedly
infectious, but we all need to be smart. We're in control of our
destiny and how we act is going to determine what comes next. So
while this is a time for excitement and celebration, it's critical
that everyone follow the guidelines and practice the safe behaviors
we know work. If everyone does their part, I believe this pilot
will be successful. Go Bills!"
About BioReference Laboratories, Inc.
BioReference
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions, and medical
groups. BioReference developed and offers test services that yield
high quality and accurate results, including a molecular test for
helping with COVID-19 diagnosis and a serology test to help
indicate possible COVID-19 exposure. The company is in network with
the five largest health plans in the
United States, operates a network of 11 laboratory
locations, and is backed by a medical staff of more than
120 M.D., Ph.D. and other
professional level clinicians and scientists. With a leading
position in the areas of genetics, women's health, maternal fetal
medicine, oncology, and urology, BioReference and its specialty
laboratories, GenPath and GeneDx, are advancing the course of
modern medicine. For more information, visit
www.bioreference.com.
About OPKO Health
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
BioReference's testing, the availability of testing and the role
and value of the information provided and its impact on decisions,
as well as other non-historical statements about our expectations,
beliefs or intentions regarding our business, technologies and
products, financial condition, strategies or prospects. Many
factors could cause our actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements. These factors include those described
in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to
be filed with the Securities and Exchange Commission and in its
other filings with the Securities and Exchange Commission. In
addition, forward-looking statements may also be adversely affected
by general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/buffalo-bills-and-opko-healths-bioreference-laboratories-initiate-the-first-large-scale-mandatory-covid-19-fan-testing-program-301199641.html
SOURCE BioReference Laboratories, Inc